Aileron Therapeutics, Inc. - ALRN STOCK NEWS

Aileron Therapeutics, Inc. announced the closing of an underwritten registered direct offering of approximately $40 million, with $20 million in initial funding and potential additional proceeds of $20 million from warrants. The offering included 4,273,505 shares of common stock and warrants at a combined public offering price of $4.68 per share. The warrants, exercisable immediately, have an exercise price of $4.68 per share and expire in three years. Titan Partners Group served as the book-running manager for the offering.

Aileron Therapeutics, Inc. announced the pricing of an underwritten registered direct offering to raise up to $40 million under Nasdaq rules. The offering includes 4,273,505 shares of common stock and warrants to purchase an equal number of shares. The offering is expected to generate approximately $20 million in gross proceeds, with the potential for an additional $20 million from warrant exercises. The warrants have an exercise price of $4.68 per share and will expire three years from the date of issuance. The offering is subject to customary closing conditions and is expected to close on or about May 3, 2024.

Aileron Therapeutics, Inc. announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in IPF. Low-dose LTI-03 showed reductions in profibrotic proteins, increased expression of biomarkers, and was well-tolerated. Positive trends were observed in seven out of eight biomarkers. Data from Cohort 2 is expected in Q3 2024.

Aileron Therapeutics, Inc. reported its financial results for the fourth quarter and full year 2023, highlighting the successful completion of the merger with Lung Therapeutics. The company's lead product candidate, LTI-03, is expected to deliver topline results from a Phase 1b study in the third quarter of 2024. Aileron's cash runway is projected to support operations and key milestones through the fourth quarter of 2024.

Aileron Therapeutics, Inc. appoints Brian Windsor, Ph.D., as the new CEO, succeeding Manuel Aivado, M.D., Ph.D. The company focuses on developing first-in-class medicines for orphan pulmonary and fibrosis diseases. Dr. Windsor's appointment follows the acquisition of Lung Therapeutics, Inc. The transition aims to advance Aileron's pipeline of therapies for life-threatening pulmonary conditions.

Aileron Therapeutics, Inc. announces topline results from Phase 1b study of LTI-03, a novel Caveolin-1-related peptide for idiopathic pulmonary fibrosis. The company will host a virtual key opinion leader event to discuss the treatment landscape and significant unmet needs in IPF.

Aileron Therapeutics, Inc. will host a virtual key opinion leader event to discuss LTI-03, a novel Caveolin-1-related peptide for the treatment of idiopathic pulmonary fibrosis. The event will feature a panel discussion with pulmonary care medicine experts and will focus on emerging therapies, including LTI-03. Aileron's pipeline of first-in-class medicines aims to address unmet medical needs in orphan pulmonary and fibrosis indications.

Aileron Therapeutics, Inc. has acquired Lung Therapeutics, Inc., a biopharmaceutical company focused on developing therapies for orphan pulmonary and fibrosis indications. The acquisition includes multiple clinical-stage candidates, including LTI-03 for the treatment of idiopathic pulmonary fibrosis (IPF). Aileron also entered into a private placement to raise approximately $18 million to fund the ongoing Phase 1b clinical study of LTI-03 and for general corporate purposes.

Aileron Therapeutics (Nasdaq: ALRN) announced the termination of its Phase 1b trial for ALRN-6924 in patients with p53-mutated breast cancer due to severe adverse events, including Grade 4 neutropenia and alopecia. The trial assessed the drug's efficacy alongside TAC chemotherapy. Aileron is now exploring strategic alternatives to enhance shareholder value, including potential acquisition or merger opportunities, with Ladenburg Thalmann as a strategic advisor. The company's workforce will be reduced from nine to three employees. Aileron's ALRN-6924 had shown promise in prior trials, but these latest findings have necessitated a shift in focus.